CN109689058B - 治疗和预防睡眠障碍 - Google Patents

治疗和预防睡眠障碍 Download PDF

Info

Publication number
CN109689058B
CN109689058B CN201780046414.XA CN201780046414A CN109689058B CN 109689058 B CN109689058 B CN 109689058B CN 201780046414 A CN201780046414 A CN 201780046414A CN 109689058 B CN109689058 B CN 109689058B
Authority
CN
China
Prior art keywords
compound
sleep
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780046414.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109689058A (zh
Inventor
斯蒂芬·C·哈里斯
拉姆·P·卡皮尔
唐纳德·J·凯尔
加思·怀特赛德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of CN109689058A publication Critical patent/CN109689058A/zh
Application granted granted Critical
Publication of CN109689058B publication Critical patent/CN109689058B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780046414.XA 2016-07-26 2017-07-25 治疗和预防睡眠障碍 Active CN109689058B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662366960P 2016-07-26 2016-07-26
US62/366,960 2016-07-26
US201762536097P 2017-07-24 2017-07-24
US62/536,097 2017-07-24
PCT/IB2017/054506 WO2018020418A1 (en) 2016-07-26 2017-07-25 Treatment and prevention of sleep disorders

Publications (2)

Publication Number Publication Date
CN109689058A CN109689058A (zh) 2019-04-26
CN109689058B true CN109689058B (zh) 2022-03-22

Family

ID=59714072

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780046414.XA Active CN109689058B (zh) 2016-07-26 2017-07-25 治疗和预防睡眠障碍

Country Status (20)

Country Link
US (4) US10974081B2 (https=)
EP (1) EP3490563A1 (https=)
JP (2) JP7198197B2 (https=)
KR (2) KR102531366B1 (https=)
CN (1) CN109689058B (https=)
AU (2) AU2017304898B2 (https=)
BR (1) BR112019001457A2 (https=)
CA (1) CA3031388C (https=)
CL (1) CL2019000190A1 (https=)
EC (1) ECSP19014247A (https=)
IL (1) IL264294B (https=)
JO (1) JOP20190008A1 (https=)
MX (1) MX388469B (https=)
NZ (1) NZ750817A (https=)
PH (1) PH12019500177A1 (https=)
SG (1) SG11201900486WA (https=)
TN (1) TN2019000019A1 (https=)
TW (1) TWI661827B (https=)
WO (1) WO2018020418A1 (https=)
ZA (1) ZA201901055B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
KR20240160681A (ko) * 2018-01-24 2024-11-11 퍼듀 퍼머 엘피 수면 장애 치료 및 예방
CA3097445A1 (en) * 2018-04-16 2019-10-24 Technologies Hop-Child, Inc. Systems and methods for the determination of arousal states, calibrated communication signals and monitoring arousal states
KR102198846B1 (ko) * 2018-06-29 2021-01-05 다인기술 주식회사 배뇨에 관한 설문을 수행하는 방법, 시스템 및 비일시성의 컴퓨터 판독 가능 기록 매체
US11547350B2 (en) 2018-12-26 2023-01-10 Industrial Technology Research Institute Personalized parameter learning method, sleep-aid device and non-transitory computer readable medium
CN111359074B (zh) * 2018-12-26 2022-08-02 财团法人工业技术研究院 个人化参数学习方法、睡眠辅助装置及存储介质
IL284564B2 (en) * 2019-01-31 2025-07-01 Purdue Pharma Lp Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
KR20220062361A (ko) * 2019-09-13 2022-05-16 다케다 야쿠힌 고교 가부시키가이샤 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
CN117750958A (zh) 2021-05-21 2024-03-22 普渡制药公司 治疗间质性膀胱炎/膀胱疼痛综合征的方法
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法
CA3258088A1 (en) * 2022-06-24 2023-12-28 Purdue Pharma L.P. METHODS OF TREATMENT OR PREVENTION OF OVERACTIVE BLADDER SYNDROME
AU2024364388A1 (en) 2023-10-19 2026-03-19 Purdue Pharma L.P. Sunobinop for use in method of treating alcohol use disorder

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US6572891B1 (en) 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
JP4056977B2 (ja) 2002-03-29 2008-03-05 田辺三菱製薬株式会社 睡眠障害治療薬
WO2004100857A2 (en) 2003-05-07 2004-11-25 Akina, Inc. Highly plastic granules for making fast melting tablets
SA04250305B1 (ar) 2003-09-25 2008-06-02 سولفاي فارماسوتيكالز بي . في مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية
US7355045B2 (en) 2004-01-05 2008-04-08 Applera Corporation Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof
WO2006025267A1 (ja) 2004-08-31 2006-03-09 Mitsubishi Pharma Corporation Per2タンパク質レベルの低下を作用機序とする睡眠障害治療薬
US9308175B2 (en) 2006-09-15 2016-04-12 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
TW201322983A (zh) * 2007-08-31 2013-06-16 Purdue Pharma Lp 經取代之喹□啉型哌啶化合物及其用途
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
CN102105465B (zh) 2008-07-21 2015-03-11 普渡制药公司 取代的喹喔啉型桥连哌啶化合物及其用途
AU2012324015A1 (en) 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
US9040533B2 (en) * 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
US10118927B2 (en) * 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم

Also Published As

Publication number Publication date
JP7291172B2 (ja) 2023-06-14
AU2020273332B2 (en) 2022-11-24
US11738023B2 (en) 2023-08-29
JOP20190008A1 (ar) 2019-01-24
KR102531366B1 (ko) 2023-05-12
WO2018020418A1 (en) 2018-02-01
US20260007660A1 (en) 2026-01-08
AU2017304898A1 (en) 2019-03-07
EP3490563A1 (en) 2019-06-05
US12370191B2 (en) 2025-07-29
JP7198197B2 (ja) 2022-12-28
US20240058333A1 (en) 2024-02-22
AU2017304898B2 (en) 2020-08-20
TN2019000019A1 (en) 2020-07-15
ECSP19014247A (es) 2019-05-31
IL264294B (en) 2022-06-01
TWI661827B (zh) 2019-06-11
SG11201900486WA (en) 2019-02-27
MX388469B (es) 2025-03-20
US20210330994A1 (en) 2021-10-28
PH12019500177A1 (en) 2019-10-14
CL2019000190A1 (es) 2019-06-07
MX2019001036A (es) 2019-06-10
AU2020273332A1 (en) 2020-12-17
CA3031388C (en) 2023-02-14
US20190282836A1 (en) 2019-09-19
US10974081B2 (en) 2021-04-13
ZA201901055B (en) 2019-12-18
KR20210013319A (ko) 2021-02-03
IL264294A (en) 2019-02-28
KR20190029682A (ko) 2019-03-20
BR112019001457A2 (pt) 2019-05-07
KR102210209B1 (ko) 2021-02-01
CN109689058A (zh) 2019-04-26
TW201817423A (zh) 2018-05-16
CA3031388A1 (en) 2018-02-01
JP2019523269A (ja) 2019-08-22
JP2021120379A (ja) 2021-08-19
NZ750817A (en) 2020-07-31

Similar Documents

Publication Publication Date Title
CN109689058B (zh) 治疗和预防睡眠障碍
US12171762B2 (en) Sleep disorder treatment and prevention
WO2016061554A1 (en) Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof
JP2012508186A (ja) むずむず脚症候群および睡眠障害の治療

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant